Lipid Insights

What does your patient's lipid panel actually tell you and what is it missing? In this special National Lipid Day episode of Lipid Insights, host Peter H. Jones, MD, MNLA, sits down with Thomas Dayspring, MD, FACP, MNLA — widely known as "The Lipid Doctor" — for a conversation that challenges some of medicine's most entrenched assumptions about lipid risk assessment. From the clinical superiority of ApoB over LDL-C and the underrecognized atherogenic burden of Lipoprotein(a), to why HDL-C should no longer be treated as a therapeutic target, Dr. Dayspring delivers evidence-based truths that have direct implications for how clinicians assess and manage cardiovascular risk. If you order lipid panels, counsel patients on cholesterol, or manage ASCVD risk in any capacity — this episode is essential listening.Follow @drlipid on X (Twitter) and LinkedIn.https://x.com/Drlipidhttps://www.linkedin.com/in/thomas-dayspring-md-facp-fnla-3aaa876/

In this episode of Lipid Insights, host Peter H. Jones, MD, MNLA sits down with Nivedita Patni, MD, of the Department of Pediatrics at UT Southwestern Medical Center in Dallas, TX, to explore the complex landscape of pediatric dyslipidemia. Dr. Patni walks through the critical importance of tailoring management to etiology, the long-term cardiovascular and metabolic risks that hang in the balance, and why early identification is everything.Drawing on case studies and evidence-based management strategies, Dr. Patni shares practical implementation guidelines for clinicians navigating these challenging diagnoses — including the challenges that make rare lipid disorders in children so easy to overlook and so difficult to treat. She also highlights the essential role of multidisciplinary care, bringing together endocrinology, dietetics, and family support to deliver truly individualized treatment.Whether you're seeing these patients regularly or encountering them for the first time, this episode will sharpen your clinical lens and equip you with actionable strategies to make a difference early.

Childhood obesity is one of the most pressing public health challenges of our time — and its long-term cardiovascular and metabolic consequences make it essential territory for lipidologists and clinicians alike.In this episode of Lipid Insights, host Peter H. Jones, MD, MNLA sits down with Casey Berman, MD to explore the full picture: how childhood obesity is defined, why its prevalence continues to rise, and the behavioral, societal, and genetic factors fueling the epidemic. They also dive into associated comorbidities and the latest prevention and management strategies — from lifestyle modifications and pharmacotherapy to the evolving role of bariatric and metabolic surgery.A must-listen for any clinician looking to better support their youngest patients.

Join host Dr. Peter H. Jones for a special episode of Lipid Insights discussing the 2026 ACC/AHA/Multisociety Guideline on the Management of Dyslipidemia. Dr. Jones is joined by guideline author and NLA Past President Dr. Joseph Saseen and NLA President-Elect Dr. Dinesh Kalra to break down what clinicians need to know.From the restoration of LDL-C treatment goals and major conceptual shifts from the 2018 guideline, to primordial and primary prevention, risk assessment, special populations, and real-world implementation challenges, this episode covers it all. The panel also explores the guideline's expanded scope beyond LDL-C to include triglycerides, Lp(a), ApoB, and more.This is a must-listen episode for anyone involved in dyslipidemia management.Read the Guidelines here: https://www.jacc.org/doi/10.1016/j.jacc.2025.11.016

In this episode of Lipid Insights, we explore the NLA's recent expert meta-analysis, "Low-density lipoprotein cholesterol lowering and risk of major adverse cardiovascular events in primary prevention trials." Lead author Dinesh K. Kalra, MD, MBA and key author Kevin C. Maki, PhD, CLS, MNLA join host Alan S. Brown, MD, MHA, MNLA to examine the relationship between LDL-C reduction and major adverse cardiovascular events in primary prevention trials. Together, they break down the findings, clinical implications, and why early LDL-C lowering remains central to preventing first cardiovascular events.Read the meta-analysis: https://www.lipidjournal.com/article/S1933-2874(26)00039-5/fulltext 

In this episode of Lipid Insights, host Dr. Peter Jones is joined by renowned experts Robert H. Eckel, MD, FNLA and Samuel M. Kim, MD for a thoughtful discussion on the complex relationship between obesity, weight loss, and cardiometabolic health. 

Hosted by Dave Dixon, PharmD, CLS, FNLA, this episode features an in-depth discussion with three key authors of the NLA’s new statement providing updated guidance on diagnosis, management, and treatment of FH. Together, they review the most important updates in the new guidance, including recommendations for earlier identification, the role of genetic testing and cascade screening, updated LDL-cholesterol treatment targets, and the integration of newer lipid-lowering therapies. The conversation also addresses practical considerations for managing FH across the lifespan, from pediatric care to special populations, with a focus on translating evidence-based recommendations into real-world clinical practice.You can watch the video version of this podcast HERE.You can read the official NLA consensus statement published open-access in the Journal of Clinical Lipidology HERE.Podcast listeners can claim credit for listening to the podcast HERE.This podcast has been approved for AMA PRA Category 1 Credit™. This activity is eligible for ACPE, ANCC, and CDR credit.

Dr. Peter Jones welcomes Dr. Nihar Desai for a forward-looking discussion on the future of cardiovascular prevention. From implementation science to performance measurement, this episode challenges traditional approaches and explores how innovation, systems thinking, and accountability can reshape how we achieve lasting cardiovascular health.Guest:Nihar R. Desai, MD, MPHAssociate Professor of MedicineYale School of MedicineVice Chief, Section of Cardiovascular MedicineYale New Haven Health SystemNew Haven, CTWatch the Video

In this episode of Lipid Insights, host Dr. Peter Jones is joined by Dr. Harold Bays for a practical, clinician-focused discussion of the ATTAIN Study and what it means for everyday lipid management. Together, they walk through the key questions clinicians ask when new evidence emerges: what the study set out to evaluate, how to interpret the findings in context, and where the results may (or may not) shift decision-making at the point of care.Dr. Bays brings a real-world lens to the conversation—highlighting how study design, patient selection, endpoints, and background therapy can influence how we apply data in practice. The episode emphasizes translating evidence into action, from identifying the right patients to aligning therapeutic strategy with risk, goals, and adherence realities. Whether you’re looking to sharpen your interpretation of clinical trial data or refine your approach to lipid-related risk reduction, this discussion offers clear takeaways you can use immediately.YouTube Link:https://youtu.be/s65WHd1WjII

Join host Peter Jones, MD, MNLA for a conversation on the evolving landscape of metabolic health in youth. In this episode, Dr. Jones is joined by two leading pediatric experts—Don Wilson, MD, FNLA and Amy Shah, MD, FNLA—to explore practical strategies and emerging research on managing lipids and metabolic syndrome in younger populations.The discussion highlights key findings from their recently published special issue in the Journal of Clinical Lipidology, offering listeners evidence-based insights and clinical pearls to improve outcomes in pediatric and adolescent care. Whether you’re a clinician, researcher, or simply passionate about preventive cardiometabolic health, this episode delivers expert perspectives you won’t want to miss.

Rewriting the Risk Equation: The Expanding Role of Lp(a) in Atherosclerotic DiseaseHosted by Dr. Underberg, the Rewriting the Risk Equation: The Expanding Role of Lp(a) in Atherosclerotic Disease podcast is designed to equip clinicians with the latest evidence on Lp(a) biology, screening strategies, and current and emerging therapeutic options. Along with Drs. Soffer, Kulkarni and Wilkinson, they will explore the integration of Lp(a) assessment into routine practice, implications for high-risk populations including those with familial hypercholesterolemia (FH), and strategies to mitigate cardiovascular risk until targeted therapies become available. You can watch a video version of this podcast by Clicking Here

Can genetic scores unlock better outcomes for patients with FH? This special Snippet from our Lipid Insights podcast series dives into the award-winning abstract from #NLASessions 2025, exploring how polygenic risk scores for coronary artery disease may transform ASCVD prediction and management. Tune in and see what’s next in lipid science.Guest HostDaniel E. Soffer, MD, MNLAUniversity of Pennsylvania Health SystemInternal Medicine/Clinical LipidologyPerelman Center for Advanced MedicinePhiladelphia, PAGuestAlexis Baass, MD, MSc, FNLA Alexis Baass, MD, MSc, FNLADirector of the LipidsNutrition and Cardiovascular Prevention ClinicMontreal Clinical Research InstituteMontreal, QC, CanadaClick here to see the video version of this episode

In this episode of Lipid Insights, Dr. Peter Jones and guest Dr. Kevin Maki explore whether beef deserves its long-standing reputation as a driver of cardiovascular disease. Drawing on a recent systematic review and meta-analysis, they examine beef’s impact on cholesterol, blood pressure, and other key CVD risk factors—providing fresh perspective for clinicians navigating dietary guidance.This podcast has been approved for AMA PRA Category 1 Credit™. This activity is eligible for ACPE, ANCC, and CDR credit. To read full accreditation information and claim credit, CLICK HERE. 

In this short episode, guest host Dr. Dan Soffer chats with Dr. Joshua Hyman, the Young Investigator Award winner at #NLASessions 2025. Dr. Hyman gives a quick overview of his award-winning abstract and shares insights from his work in advancing lipid research.

Hosted by Dr. Dan Soffer, this conversation brings NLA President Dr. Willard and Beth Jackson together to unpack the Association’s guidance, “LDL Cholesterol Management Simplified in Adults – Lower for Longer is Better.” The trio turns a big message into practical moves: why lifetime LDL exposure matters, who needs more aggressive targets, and how to streamline therapy choices from high-intensity statins to add-ons (ezetimibe, PCSK9-directed options) when goals aren’t met. They share real-world tactics on adherence, stepwise intensification, shared decision-making, and navigating special populations—all in a clear, clinic-ready format.Read the featured article HEREWatch this video on YouTube HEREGuest HostDaniel E. Soffer, MD, MNLA University of Pennsylvania Health SystemInternal Medicine/Clinical LipidologyPerelman Center for Advanced MedicinePhiladelphia, PAKaye-Eileen Willard, MD, FNLAMedical Director Lipid ClinicPhysician Advisor, Ascension SE WisconsinChief of Staff Ascension All SaintsChair Joint Chiefs of Staff Ascension SE WisconsinRacine, WIBeth Jackson, MSN, ACNS-BC, CLS, FNLAPrevention Lipid ClinicApp ManagerBaylor Scott and WhiteDivision of Cardiology Temple, TX

In this episode, Alan Brown, MD, MHA, MNLA sits down with Rebecca Juliano, PhD, MPhil, MA to discuss a first-in-human study of an investigational ANGPTL4 inhibitory antibody. The conversation explores how this novel therapeutic approach safely and effectively reduces plasma triglycerides and remnant cholesterol—key drivers of residual cardiovascular risk. Listeners will gain insight into the mechanism of action, clinical significance, and potential role of ANGPTL4 inhibition in the evolving landscape of lipid management.View this Episode on YouTube HERE

Explore the NLA’s new guidance on building effective, team-based approaches to improve outcomes in clinical lipidology and cardiometabolic care.Read the Expert Clinical Review HEREView this Episode on YouTube HEREGuest HostDaniel E. Soffer, MD, MNLAUniversity of Pennsylvania Health SystemInternal Medicine/Clinical LipidologyPerelman Center for Advanced MedicinePhiladelphia, PAGuestsMary Katherine Cheeley, PharmD, CLS, FNLAExecutive Director, Ambulatory Pharmacy ServicesGrady Health SystemAtlanta, GAMichael Wilkinson, MD, FNLAAssociate ProfessorDivision of Cardiovascular MedicineUC San DiegoSan Diego, CA

Dive into the complexities of Persistent Chylomicronemia with this special episode recorded live at the recent National Lipid Association Scientific Sessions. Guest host Christie Ballantyne, MD, is joined by leading experts Seyedmohammad Saadatagah, MD, Erin Michos, MD, and Daniel Gaudet, MD, PhD, to break down key takeaways from the newly released Joint Expert Clinical Consensus from the National Lipid Association and the American Society for Preventive Cardiology: Recognition and Management of Persistent Chylomicronemia. This engaging discussion explores diagnostic challenges, treatment strategies, and why recognizing this condition is critical to preventing severe complications like pancreatitis. Don’t miss this deep dive into one of the most misunderstood lipid disorders. The video episode is available on YouTube: https://youtu.be/7jbMin8Lk3s 

Alan Brown, MD, FNLA talks with Robert Hegele, MD, FRCPC about the Arrowhead Pharma and their data on Palisade Phase 3.

Alan Brown, MD, FNLA talks with Christie Ballantyne, MD, FNLA about the publication of "A Focused Update to the 2019 NLA Scientific Statement On The Use of Lp(a) in Clinical Practice"

Alan Brown, MD, FNLA talks with Carol F. Kirkpatrick, PhD, MPH, RDN, CLS, FNLA and Kevin C Maki, PhD, CLS, FNLA, FTOS, FACN to discuss Nutrition Interventions for Adults with Dyslipidemia. 

Alan Brown, MD, FNLA talks with Mary Katherine Cheeley, PharmD, FNLA about the persistence of statin underuse i practice.

This episodes turns the tables as NLA's own Dan Soffer pitches the questions to Lipid Insights regular host Alan Brown.

Dr. Alan Brown sits down with Zareen Farukhi, MD, MPH,  Associate Physician at Brigham and Women's Hospital and Instructor at Harvard; and Rachel M. Bond, MD, FACC, System Director for Women's Health at Dignity Health and Assistant Professor of Medicine at Creighton University. Today, the discuss important topics in Women's Cardiovascular Health.

Dr. Alan Brown sits down with Kim Birtcher, PharmD, Adjunct Clinical Professor at the University of Houston College of Pharmacy to discuss approaches to cardiovascular risk reduction in the age of modern therapies such as PCSK9 inhibitors.

Dr. Alan Brown sits down with the 2020 Donald Hunninghake, MD, Familial Hypercholesterolemia (FH) Abstract Award winner to discuss genetic variations in patients with very high LDL cholesterol including familial hypercholesterolemia.

Join Dr. Alan Brown and Dr. Robert Rosenson as they discuss evinacumab, a new therapeutic option for treating dyslipidemia.

Dr. Alan Brown sits down with Dr. Carl Orringer and Dr. Michael Blaha to take a deeper look at the recent NLA scientific statement on CAC Scoring.

Join Dr. Alan Brown as he sits down with Dr. Deepak Bhatt and Dr. Christie Ballantyne to discuss the outcomes of recent omega 3 trials and the controversies that surround them.

Join Dr. Alan Brown as he sits down with Dr. Deepak Bhatt and Dr. Christie Ballantyne to discuss the outcomes of recent omega 3 trials and the controversies that surround them.

Dr. Alan Brown sat down with Dr. Christie Ballantyne and Dr. Scott Wright to gain insight on two new lipid therapies during NLA's LipidPALOOZA.

Dr. Alan Brown sits down with Dr. Rob Hegele to gain insights on the complexities of genetic testing in dyslipidemia.

Dr. Alan Browns sits down with Dr. David Davidson to provide insight into the gaps in treatment of patients with Familial Hypercholesterolemia.

Join Dr. Alan Brown and Dr. Kim Birtcher as they discuss the complexities of prior authorizations and what methods providers can utilize to obtain prior authorization for PCSK9i.Click here for additional materials.